Cas:4500-31-6 2-(dicyclohexylamino)ethanol manufacturer & supplier

Chemical Name:2-(dicyclohexylamino)ethanol

CAS.NO:4500-31-6

Synonyms:2-dicyclohexylamino-ethanol;2-Dicyclohexylamino-aethanol;EINECS 224-810-0;N-<2-Hydroxy-aethyl>-dicyclohexylamin;N,N-Dicyclohexyl-aminoethanol;N,N-Dicyclohexylethanolamine

Molecular Formula:C₁₄H₂₇NO

Molecular Weight:225.37000

HS Code:2922199090

Physical and Chemical Properties:

Melting point:37ºC

Boiling point:352.1ºC at 760mmHg

Density:0.99g/cm3

Index of Refraction:1.511

PSA:23.47000

Exact Mass:225.20900

LogP:2.94610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-dicyclohexylamino-ethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-Dicyclohexylethanolamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N-Dicyclohexyl-aminoethanol Use and application,2-Dicyclohexylamino-aethanol technical grade,usp/ep/jp grade.

Related News: Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. 2-(dicyclohexylamino)ethanol manufacturer As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters. 2-(dicyclohexylamino)ethanol supplier Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API. 2-(dicyclohexylamino)ethanol vendor Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. 2-(dicyclohexylamino)ethanol factory Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study.